---
document_datetime: 2025-12-02 05:14:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mozobil.html
document_name: mozobil.html
version: success
processing_time: 0.1089564
conversion_datetime: 2025-12-27 15:48:41.837084
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mozobil

[RSS](/en/individual-human-medicine.xml/66842)

##### Authorised

This medicine is authorised for use in the European Union

plerixafor Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mozobil](#news-on)
- [More information on Mozobil](#more-information-on-mozobil-803)
- [More information on Mozobil](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mozobil is a medicine used to mobilise blood stem cells from a patient's bone marrow so that they can be collected and used later for transplantation in the same patient.

Mozobil is used together with the hormone granulocyte-colony stimulating factor (G-CSF) and is only for patients in whom collection of stem cells is difficult.

The patients who are given Mozobil are:

- adults with lymphoma or multiple myeloma (types of blood cancer);
- children from 1 year of age who have lymphoma or solid tumours.

Mozobil contains the active substance plerixafor.

Expand section

Collapse section

## How is Mozobil used?

Mozobil is given as an injection under the skin. The medicine can only be obtained with a prescription and treatment should only be started and supervised by a doctor who has experience in treating cancer or blood disorders. After the patient has been given Mozobil, the patient's stem cells are extracted from the blood and stored before transplantation. Because of this, treatment should be carried out in collaboration with a specialised centre that has experience with this type of procedure and can monitor the stem cells.

Mozobil is used together with G-CSF. G-CSF is used on its own for 4 days before Mozobil is added. Mozobil is given 6 to 11 hours before the patient's blood is taken and the stem cells are extracted. It can be used for up to 7 consecutive days. The dose depends on the bodyweight of the patient.

For more information about using Mozobil, see the package leaflet or contact your doctor or pharmacist.

## How does Mozobil work?

Mozobil is used to mobilise the stem cells from the bone marrow so they can be released into the blood. The active substance in Mozobil, plerixafor, works by blocking the activity of a protein called the 'CXCR4 chemokine receptor'. This protein normally helps to keep stem cells within the bone marrow. By blocking its activity, Mozobil allows the stem cells to be released into the blood, so that they can be collected.

## What benefits of Mozobil have been shown in studies?

In two main studies involving 298 adults with non-Hodgkin's lymphoma and 302 adults with multiple myeloma, more patients who received Mozobil achieved the target number of stem cells and had successful engraftment of stem cells (the cells started growing and producing normal blood cells after transplantation) than patients who received placebo (a dummy treatment). In both studies the patients were also receiving G-CSF.

Among the adults with lymphoma, 59% (89 out of 150) of those receiving Mozobil achieved the target number of stem cells within 4 collection days, compared with 20% (29 out of 148) of the patients receiving placebo. Among the adults with multiple myeloma, 72% (106 out of 148) of those receiving Mozobil achieved the target number of stem cells within 4 collection days, compared with 34% (53 out of 154) of the patients receiving placebo.

In a main study involving 45 children with lymphoma or solid tumours, 80% (24 out of 30) of patients who received Mozobil had at least a doubling of the number of stem cells in the blood, compared with 29% (4 out of 14) patients who received standard mobilisation treatment alone.

## What are the risks associated with Mozobil?

The most common side effects with Mozobil (which may affect more than 1 patient in 10) are diarrhoea, nausea (feeling sick) and reactions at the site of injection. For the full list of side effects and restrictions with Mozobil, see the package leaflet.

## Why is Mozobil authorised in the EU?

The European Medicines Agency decided that Mozobil's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mozobil?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mozobil have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mozobil is continuously monitored. Side effects reported with Mozobil are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mozobil

Mozobil received a marketing authorisation valid throughout the EU on 31 July 2009.

Mozobil : EPAR - Medicine overview

Reference Number: EMA/254533/2019

English (EN) (84.48 KB - PDF)

**First published:** 20/08/2009

**Last updated:** 02/09/2019

[View](/en/documents/overview/mozobil-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-123)

български (BG) (111.28 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/bg/documents/overview/mozobil-epar-medicine-overview_bg.pdf)

español (ES) (84.38 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/es/documents/overview/mozobil-epar-medicine-overview_es.pdf)

čeština (CS) (110.46 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/cs/documents/overview/mozobil-epar-medicine-overview_cs.pdf)

dansk (DA) (83.44 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/da/documents/overview/mozobil-epar-medicine-overview_da.pdf)

Deutsch (DE) (85.04 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/de/documents/overview/mozobil-epar-medicine-overview_de.pdf)

eesti keel (ET) (81.86 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/et/documents/overview/mozobil-epar-medicine-overview_et.pdf)

ελληνικά (EL) (119.01 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/el/documents/overview/mozobil-epar-medicine-overview_el.pdf)

français (FR) (84.71 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/fr/documents/overview/mozobil-epar-medicine-overview_fr.pdf)

hrvatski (HR) (105.9 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/hr/documents/overview/mozobil-epar-medicine-overview_hr.pdf)

italiano (IT) (83.89 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/it/documents/overview/mozobil-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (106.51 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/lv/documents/overview/mozobil-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (107.54 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/lt/documents/overview/mozobil-epar-medicine-overview_lt.pdf)

magyar (HU) (106.7 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/hu/documents/overview/mozobil-epar-medicine-overview_hu.pdf)

Malti (MT) (109.93 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/mt/documents/overview/mozobil-epar-medicine-overview_mt.pdf)

Nederlands (NL) (84.16 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/nl/documents/overview/mozobil-epar-medicine-overview_nl.pdf)

polski (PL) (109.91 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/pl/documents/overview/mozobil-epar-medicine-overview_pl.pdf)

português (PT) (84.33 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/pt/documents/overview/mozobil-epar-medicine-overview_pt.pdf)

română (RO) (107.27 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/ro/documents/overview/mozobil-epar-medicine-overview_ro.pdf)

slovenčina (SK) (109.32 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/sk/documents/overview/mozobil-epar-medicine-overview_sk.pdf)

slovenščina (SL) (102.86 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/sl/documents/overview/mozobil-epar-medicine-overview_sl.pdf)

Suomi (FI) (83.47 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/fi/documents/overview/mozobil-epar-medicine-overview_fi.pdf)

svenska (SV) (83.55 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

02/09/2019

[View](/sv/documents/overview/mozobil-epar-medicine-overview_sv.pdf)

Mozobil : EPAR - Risk-management-plan summary

English (EN) (70.63 KB - PDF)

**First published:** 02/09/2019

[View](/en/documents/rmp-summary/mozobil-epar-risk-management-plan-summary_en.pdf)

## Product information

Mozobil : EPAR - Product Information

English (EN) (420.78 KB - PDF)

**First published:** 20/08/2009

**Last updated:** 31/07/2024

[View](/en/documents/product-information/mozobil-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-544)

български (BG) (401.12 KB - PDF)

**First published:**

31/07/2024

[View](/bg/documents/product-information/mozobil-epar-product-information_bg.pdf)

español (ES) (496.33 KB - PDF)

**First published:**

31/07/2024

[View](/es/documents/product-information/mozobil-epar-product-information_es.pdf)

čeština (CS) (351.23 KB - PDF)

**First published:**

31/07/2024

[View](/cs/documents/product-information/mozobil-epar-product-information_cs.pdf)

dansk (DA) (307.61 KB - PDF)

**First published:**

31/07/2024

[View](/da/documents/product-information/mozobil-epar-product-information_da.pdf)

Deutsch (DE) (503.32 KB - PDF)

**First published:**

31/07/2024

[View](/de/documents/product-information/mozobil-epar-product-information_de.pdf)

eesti keel (ET) (488.18 KB - PDF)

**First published:**

31/07/2024

[View](/et/documents/product-information/mozobil-epar-product-information_et.pdf)

ελληνικά (EL) (602.8 KB - PDF)

**First published:**

31/07/2024

[View](/el/documents/product-information/mozobil-epar-product-information_el.pdf)

français (FR) (475.17 KB - PDF)

**First published:**

31/07/2024

[View](/fr/documents/product-information/mozobil-epar-product-information_fr.pdf)

hrvatski (HR) (423.4 KB - PDF)

**First published:**

31/07/2024

[View](/hr/documents/product-information/mozobil-epar-product-information_hr.pdf)

íslenska (IS) (559.16 KB - PDF)

**First published:**

31/07/2024

[View](/is/documents/product-information/mozobil-epar-product-information_is.pdf)

italiano (IT) (427.26 KB - PDF)

**First published:**

31/07/2024

[View](/it/documents/product-information/mozobil-epar-product-information_it.pdf)

latviešu valoda (LV) (549.14 KB - PDF)

**First published:**

31/07/2024

[View](/lv/documents/product-information/mozobil-epar-product-information_lv.pdf)

lietuvių kalba (LT) (557.32 KB - PDF)

**First published:**

31/07/2024

[View](/lt/documents/product-information/mozobil-epar-product-information_lt.pdf)

magyar (HU) (545.44 KB - PDF)

**First published:**

31/07/2024

[View](/hu/documents/product-information/mozobil-epar-product-information_hu.pdf)

Malti (MT) (557.33 KB - PDF)

**First published:**

31/07/2024

[View](/mt/documents/product-information/mozobil-epar-product-information_mt.pdf)

Nederlands (NL) (502.26 KB - PDF)

**First published:**

31/07/2024

[View](/nl/documents/product-information/mozobil-epar-product-information_nl.pdf)

norsk (NO) (480.94 KB - PDF)

**First published:**

31/07/2024

[View](/no/documents/product-information/mozobil-epar-product-information_no.pdf)

polski (PL) (538.33 KB - PDF)

**First published:**

31/07/2024

[View](/pl/documents/product-information/mozobil-epar-product-information_pl.pdf)

português (PT) (513.8 KB - PDF)

**First published:**

31/07/2024

[View](/pt/documents/product-information/mozobil-epar-product-information_pt.pdf)

română (RO) (544.67 KB - PDF)

**First published:**

31/07/2024

[View](/ro/documents/product-information/mozobil-epar-product-information_ro.pdf)

slovenčina (SK) (440.02 KB - PDF)

**First published:**

31/07/2024

[View](/sk/documents/product-information/mozobil-epar-product-information_sk.pdf)

slovenščina (SL) (541.42 KB - PDF)

**First published:**

31/07/2024

[View](/sl/documents/product-information/mozobil-epar-product-information_sl.pdf)

Suomi (FI) (488.91 KB - PDF)

**First published:**

31/07/2024

[View](/fi/documents/product-information/mozobil-epar-product-information_fi.pdf)

svenska (SV) (575.58 KB - PDF)

**First published:**

31/07/2024

[View](/sv/documents/product-information/mozobil-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/N/0000184403 16/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mozobil : EPAR - All Authorised presentations

English (EN) (14.78 KB - PDF)

**First published:** 20/08/2009

**Last updated:** 09/10/2014

[View](/en/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-1)

български (BG) (85.94 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/bg/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.93 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/es/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_es.pdf)

čeština (CS) (89.4 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/cs/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.07 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/da/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.91 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/de/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.7 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/et/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (82.37 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/el/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_el.pdf)

français (FR) (13.71 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/fr/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (97.76 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/hr/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.84 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/is/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.87 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/it/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (86.57 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/lv/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (49.77 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/lt/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (87.42 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/hu/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (88.56 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/mt/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.78 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/nl/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.11 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/no/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_no.pdf)

polski (PL) (93.38 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/pl/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.89 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/pt/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_pt.pdf)

română (RO) (83.6 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/ro/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (89.74 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/sk/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.13 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/sl/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.71 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/fi/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.78 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

09/10/2014

[View](/sv/documents/all-authorised-presentations/mozobil-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mozobil Active substance Plerixafor International non-proprietary name (INN) or common name plerixafor Therapeutic area (MeSH)

- Multiple Myeloma
- Hematopoietic Stem Cell Transplantation
- Lymphoma

Anatomical therapeutic chemical (ATC) code L03AX16

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.

## Authorisation details

EMA product number EMEA/H/C/001030 Marketing authorisation holder

Sanofi B.V.

Paasheuvelweg 25

Opinion adopted 29/05/2009 Marketing authorisation issued 30/07/2009 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mozobil : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (139.29 KB - PDF)

**First published:** 31/07/2024

[View](/en/documents/procedural-steps-after/mozobil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mozobil : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (254.43 KB - PDF)

**First published:** 15/04/2010

**Last updated:** 31/07/2024

[View](/en/documents/procedural-steps-after/mozobil-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Mozobil-H-C-001030-II-0034 : EPAR - Assessment report

Reference Number: EMA/243012/2019

English (EN) (2.09 MB - PDF)

**First published:** 02/09/2019

[View](/en/documents/variation-report/mozobil-h-c-001030-ii-0034-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Mozobil (II-34)

Adopted

Reference Number: EMA/CHMP/198032/2019

English (EN) (72.74 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mozobil-ii-34_en.pdf)

Mozobil-H-C-PSUSA-00002451-201612 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/CHMP/674195/2017

English (EN) (69.12 KB - PDF)

**First published:** 12/10/2017

**Last updated:** 12/10/2017

[View](/en/documents/scientific-conclusion/mozobil-h-c-psusa-00002451-201612-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Mozobil : EPAR - Public assessment report

English (EN) (1.45 MB - PDF)

**First published:** 20/08/2009

**Last updated:** 20/08/2009

[View](/en/documents/assessment-report/mozobil-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Mozobil

Reference Number: EMEA/CHMP/307173/2009

English (EN) (78.4 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-mozobil_en.pdf)

#### News on Mozobil

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019) 29/03/2019

#### More information on Mozobil

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-04-227) on 20 October 2004. Mozobil was withdrawn from the Community register of orphan medicinal products in August 2021 at the end of the 12-year period of market exclusivity.

#### More information on Mozobil

- [EMEA-000174-PIP01-07-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000174-pip01-07-m03)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/07/2024

## Share this page

[Back to top](#main-content)